title: Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.
abstract: Cyclosporine A (CsA) efficacy and safety have been proven in various dermatoses both in adults and in children even as long-term treatment. Over the last 25 years, Italian dermatologists have gathered relevant experience about CsA treatment for psoriasis and atopic dermatitis. This paper has been developed by an Italian Consensus Conference and it is aimed at providing recommendations based on real-world clinical experience in adult patients, consistent with efficacy and safety data arising from the scientific literature. The paper is mainly focused on the analysis of the optimal therapeutic schemes for psoriasis and atopic dermatitis, in terms of doses and treatment duration, according to individual characteristics and to the severity of the disease. Moreover, it overviews ideal management, taking into account pharmacological interactions, influence of comorbidities, and the most common adverse events related to CsA treatment.
authors.affiliation: IRCCS Galeazzi, University of Milan, Milan, Italy - giampiero.girolomoni@univr.it.
authors.forename: G
authors.initials: G
authors.lastname: Altomare
authors.forename: F
authors.initials: F
authors.lastname: Ayala
authors.forename: F
authors.initials: F
authors.lastname: Bardazzi
authors.forename: G
authors.initials: G
authors.lastname: Bellia
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
authors.forename: D
authors.initials: D
authors.lastname: Colombo
authors.forename: M L
authors.initials: ML
authors.lastname: Flori
authors.forename: G
authors.initials: G
authors.lastname: Girolomoni
authors.forename: G
authors.initials: G
authors.lastname: Micali
authors.forename: A
authors.initials: A
authors.lastname: Parodi
authors.forename: K
authors.initials: K
authors.lastname: Peris
authors.forename: G A
authors.initials: GA
authors.lastname: Vena
mesh_terms: D000328:Adult; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004198:Disease Susceptibility; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005260:Female; D018565:Food-Drug Interactions; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007239:Infections / Q000209:etiology; D007674:Kidney Diseases / Q000139:chemically induced / Q000175:diagnosis; D009369:Neoplasms / Q000209:etiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000517:prevention & control; D011565:Psoriasis / Q000188:drug therapy; D011788:Quality of Life; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine